Eli Lilly’s weight-loss and diabetes drugs are no longer in shortage, says FDA
The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage signaling that the company has succeeded in expanding manufacturing.
Lilly has 11 obesity drugs in its pipeline and wants to develop more treatments for Alzheimer's disease, ALS and other brain ...
Lilly will add the center to a site in Lebanon, Indiana, where it is already spending about $9 billion to improve ...
Health care stocks underperformed the broader market in 2023, with many companies falling short of their profit targets, and ...
In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Buy rating on Eli Lilly & Co (LLY – Research ...
As Eli Lilly has surged to become the most valuable company in biopharma—with a market cap now more than twice that of ...
U.S. drugmaker Eli Lilly said on Wednesday it will invest $4.5 billion to create a new center for advanced manufacturing and ...
We recently published a list of 10 Best Healthcare Stocks To Buy According to Hedge Funds. In this article, we are going to ...
ELI LILLY Inc. LLY today experienced a Power Inflow, a significant event for those who follow where smart money goes and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback